Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hiroaki Wakimoto, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Hiroaki Wakimoto and Khalid Shah.
Connection Strength

2.631
  1. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021 06; 39(6):707-722.
    View in: PubMed
    Score: 0.241
  2. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902.
    View in: PubMed
    Score: 0.237
  3. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochim Biophys Acta Rev Cancer. 2021 01; 1875(1):188458.
    View in: PubMed
    Score: 0.235
  4. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
    View in: PubMed
    Score: 0.208
  5. CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Sci Transl Med. 2018 07 11; 10(449).
    View in: PubMed
    Score: 0.201
  6. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol. 2018 01 22; 20(2):215-224.
    View in: PubMed
    Score: 0.194
  7. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017 10 15; 141(8):1671-1681.
    View in: PubMed
    Score: 0.187
  8. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017 07 25; 114(30):E6157-E6165.
    View in: PubMed
    Score: 0.187
  9. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther. 2015 Jan; 23(1):108-18.
    View in: PubMed
    Score: 0.155
  10. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014 Jun; 106(6):dju090.
    View in: PubMed
    Score: 0.150
  11. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16642-7.
    View in: PubMed
    Score: 0.134
  12. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.
    View in: PubMed
    Score: 0.134
  13. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011 Jan 01; 71(1):154-63.
    View in: PubMed
    Score: 0.118
  14. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
    View in: PubMed
    Score: 0.106
  15. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4822-7.
    View in: PubMed
    Score: 0.105
  16. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.